Kezar Life Sciences (FRA:2KZ) Debt-to-Equity : 0.11 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Kezar Life Sciences Debt-to-Equity?

Kezar Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €4.08 Mil. Kezar Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €12.74 Mil. Kezar Life Sciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €155.59 Mil. Kezar Life Sciences's debt to equity for the quarter that ended in Mar. 2024 was 0.11.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Kezar Life Sciences's Debt-to-Equity or its related term are showing as below:

FRA:2KZ' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.07 Max: 0.11
Current: 0.11

During the past 8 years, the highest Debt-to-Equity Ratio of Kezar Life Sciences was 0.11. The lowest was 0.04. And the median was 0.07.

FRA:2KZ's Debt-to-Equity is ranked better than
57.26% of 1074 companies
in the Biotechnology industry
Industry Median: 0.15 vs FRA:2KZ: 0.11

Kezar Life Sciences Debt-to-Equity Historical Data

The historical data trend for Kezar Life Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kezar Life Sciences Debt-to-Equity Chart

Kezar Life Sciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.08

0.04

0.07

0.08

0.10

Kezar Life Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.08	0.09	0.09	0.10	0.11

Competitive Comparison of Kezar Life Sciences's Debt-to-Equity

For the Biotechnology subindustry, Kezar Life Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kezar Life Sciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kezar Life Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Kezar Life Sciences's Debt-to-Equity falls into.

Kezar Life Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Kezar Life Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.762	+	14.6)	/	172.002
	=	0.10

Kezar Life Sciences's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.083	+	12.74)	/	155.591
	=	0.11

Kezar Life Sciences (FRA:2KZ) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Kezar Life Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Kezar Life Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Kezar Life Sciences (FRA:2KZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kezar Life Sciences Inc (FRA:2KZ) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

KZR:USA 2KZ:Germany

Address

4000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.kezarlifesciences.com

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as KZR-616, and the protein secretion program.

Kezar Life Sciences (FRA:2KZ) Headlines

No Headlines